Atezolizumab + bevacizumab

Atezolizumab and bevacizumab at a glance

Atezolizumab, commonly called Tecentriq, is immunotherapy. Bevacizumab, commonly called Avastin, is targeted therapy; licensed biosimilar brands also exist. The two medicines do different jobs and have different safety checks. A brand substitution should always be recorded by your hospital, including the product and route used.

This guide focuses on the two-drug treatment commonly used for a type of primary liver cancer called hepatocellular carcinoma, or HCC. Treatment usually takes place every three weeks. Both drugs may be infusions; an under-the-skin atezolizumab formulation is available in some settings. Bevacizumab remains an intravenous infusion in this combination.

Blood pressure, urine protein, liver function and possible immune inflammation need attention throughout treatment. A normal appointment last week does not make a new symptom safe to ignore. Side effects from atezolizumab can begin after treatment has stopped. Keep your treatment alert card with you.

How the combination works

Some cancer cells use a protein called PD-L1 to reduce immune-cell activity. Atezolizumab blocks this interaction, allowing an immune response against cancer. The immune response may also affect healthy organs, which explains why symptoms such as diarrhoea or breathlessness need assessment even when you have no fever.

Bevacizumab blocks VEGF, a signal involved in forming blood vessels. This can interfere with the blood supply supporting a tumour. Blood vessels also have normal roles in healing and maintaining healthy tissues. Treatment can therefore raise blood pressure, cause protein to leak into urine, impair healing or contribute to bleeding and clots.

Combining the medicines is intended to improve cancer control in an appropriate patient. It is not possible to predict an individual's response from the mechanism alone. Your oncologist will explain the treatment goal and how scans, symptoms and laboratory results will be used together to judge benefit.

How the team decides whether it is suitable

The team considers your diagnosis, liver function, previous treatment, general fitness and bleeding risk. HCC often develops in a liver already affected by cirrhosis. The cancer and the underlying liver condition both matter when choosing treatment; a treatment suitable for one person with HCC may be unsuitable for another.

Tell the team about previous bleeding from the stomach or food pipe, vomiting blood, black stools, recent surgery, wounds that have not healed, stroke, heart disease and poorly controlled blood pressure. Also mention inflammatory bowel disease, autoimmune illness, organ transplantation and previous severe reactions to antibody treatments.

A transplant or an autoimmune condition requires specialist discussion because activating immunity can worsen existing inflammation or damage a transplanted organ. Medicines that suppress immunity may affect planning, but should not be stopped without the prescriber. Availability, funding and the exact licensed formulation vary between countries; this guide does not establish Indian regulatory approval.

Before treatment starts

Checks for bleeding and liver health

An assessment for enlarged veins called varices is important before bevacizumab in HCC. Varices can develop in the food pipe or stomach when pressure builds in the blood vessels around a diseased liver. They can bleed heavily. The US Avastin information recommends evaluating for varices within six months before starting; an endoscopy and treatment of high-risk varices may be needed.

An endoscopy is a camera examination of the upper digestive tract. Ask whether your result is recent enough and whether any identified varices need treatment before the first dose. Recent bleeding or untreated high-risk varices can change the treatment choice. Having no stomach pain does not exclude this problem.

Baseline checks usually include blood counts, liver and kidney function, thyroid function, glucose, blood pressure and urine testing. Your liver team may also assess hepatitis infection and any antiviral treatment. Bring all current prescriptions, including water tablets, blood-pressure medicines and treatments for liver disease.

Make a practical safety plan

Save the hospital's daytime and out-of-hours numbers. Ask what temperature threshold your unit uses, where to attend outside office hours and whether to keep a home blood-pressure record. Record your usual bowel pattern and any existing cough or breathlessness so changes are easier to describe.

Tell the team about planned dental work or an operation before dates are fixed. Discuss pregnancy possibility, contraception and fertility before treatment starts. If travel to the hospital is difficult, explain this early so blood tests, appointments and urgent assessment arrangements are clear.

How treatment is given

Infusions and injections

A common HCC schedule is intravenous atezolizumab 1,200 mg followed by bevacizumab 15 mg per kilogram every three weeks. Atezolizumab has other approved schedules, and formulations differ. The prescription and appointment calendar supplied by your team take priority over a dose printed in general information.

The first intravenous atezolizumab dose commonly runs over 60 minutes, with later doses over 30 minutes if tolerated. Bevacizumab commonly starts over 90 minutes, then 60 minutes and later 30 minutes if there is no reaction. Checks, preparation and observation make the visit longer than the infusion time.

Where prescribed, subcutaneous atezolizumab is injected into the thigh over about seven minutes. It is a different preparation with a different dose from intravenous atezolizumab. It does not remove the need for bevacizumab's infusion or for the same safety monitoring. Confirm which formulation you are receiving.

During and between appointments

Tell the nurse immediately if you develop chills, itching, flushing, chest or back discomfort, dizziness, wheezing or swelling during treatment. Staff can stop or slow administration and treat a reaction. After discharge, throat swelling, severe breathing difficulty or collapse requires emergency care.

The team may prescribe supportive medicines according to your circumstances. Take them as directed. If a dose is delayed, call the unit; there is no catch-up double infusion. A delay may allow a side effect or infection to settle and does not automatically mean the cancer is progressing.

Monitoring and checking response

At reviews, describe changes since the previous appointment rather than only how you feel that morning. Bring a short record of bowel movements, symptoms, blood pressure if requested, and any new medicines. Mention symptoms that resolved, including bleeding, dizziness or a brief episode of chest pain.

Blood tests look for liver or kidney injury and changes in hormones or blood sugar. Urine testing detects protein that may be present before you notice swelling. More detailed urine collection or a treatment pause may be needed if protein levels rise. Blood pressure needs regular checks even when you feel well.

Scans are arranged at intervals appropriate to your condition. A blood marker such as AFP may contribute to HCC monitoring but cannot replace the whole assessment. Ask when the next scan is planned and how results will be discussed. New symptoms should be reported between scans rather than saved for that appointment.

Common side effects and practical care

Tiredness, appetite and nausea

Fatigue may affect concentration, walking and ordinary household tasks. Balance activity with planned rest and ask for help with demanding jobs. If tiredness changes suddenly, is accompanied by dizziness or prevents usual activities, contact the team: anaemia, dehydration, infection or hormone changes may need treatment.

Small meals and snacks may be easier than large portions. Report ongoing vomiting, weight loss or difficulty drinking. People with liver disease may have individual fluid or salt advice; do not follow a generic instruction to drink very large amounts without checking your plan. A dietitian can help match food intake to your needs.

Skin and joints

Dryness, itching, rash and aching joints can occur. Use gentle washing products, moisturise dry skin and protect it from strong sunlight. Tell the team about new rash or troublesome pain so they can assess it and choose treatment. Do not start strong steroid creams or oral steroids yourself.

Bowel changes and minor bleeding

Report new loose stools promptly, even if they initially seem manageable. Note how many more stools you are passing than usual, whether they occur at night and whether there is blood, mucus or abdominal pain. Immune bowel inflammation requires different treatment from an ordinary stomach upset.

Minor nosebleeds may occur with bevacizumab, but recurrent or prolonged bleeding needs advice. Do not assume bleeding is harmless because you have had it before. Tell the team about gum bleeding, easy bruising or blood in urine, particularly if you take medicines that affect clotting.

Important side effects to recognise

Bleeding, clots and bowel injury

Bevacizumab can cause serious bleeding, including from varices. Vomiting blood or material resembling coffee grounds, black sticky stools, coughing up significant blood, or bleeding with faintness needs emergency care. Do not drive yourself if you feel faint.

A swollen painful leg may indicate a clot. Sudden breathlessness or chest pain may indicate a clot in the lung; facial droop, arm weakness or speech difficulty may indicate a stroke. These are urgent medical problems. Severe persistent abdominal pain, especially with vomiting or fever, can indicate bowel perforation or another abdominal emergency.

Immune inflammation

Atezolizumab can cause inflammation in the lungs, bowel, liver, kidneys, heart, skin, nerves or hormone-producing glands. Report a new cough, worsening breathing, jaundice, reduced urine, persistent diarrhoea, unusual muscle weakness, severe headache or marked change in energy. Several organs can be affected together. Increased thirst and frequent urination may signal immune-related diabetes. Severe weakness with vomiting, faintness or confusion can indicate a hormone emergency. New painful eyes or visual change also requires prompt assessment.

In HCC, jaundice or worsening abdominal swelling may have several explanations, including underlying liver disease. The cause cannot reliably be decided at home. Prompt assessment helps the team distinguish treatment toxicity, infection and changes in the cancer or liver condition.

Treatment may include withholding cancer therapy and giving corticosteroids or other medicines. Some hormone problems require long-term replacement treatment. If steroids are prescribed, follow the tapering plan and do not stop abruptly. Tell other clinicians about immunotherapy even months after the last dose.

Blood pressure, kidneys and healing

High blood pressure often has no symptoms. Severe headache, confusion, seizures or visual disturbance needs urgent assessment; a rare brain condition called PRES is one possible cause. Foamy urine, ankle swelling or reduced urine should also be reported.

Bevacizumab can delay healing. The US label specifies at least 28 days before elective surgery and at least 28 days after major surgery, with adequate wound healing before treatment resumes. Your surgeon and oncologist may require a longer interval. Never arrange a treatment interruption or restart yourself.

Other medicines and vaccinations

Ask the oncology pharmacist to check prescriptions, over-the-counter medicines, Ayurvedic or herbal products and supplements. Blood thinners, antiplatelet medicines and anti-inflammatory painkillers can matter when assessing bleeding. Do not stop a prescribed blood thinner yourself: preventing a clot may still be essential.

Steroids and other immune-suppressing medicines require coordination with the team. This does not mean steroids must be avoided when needed to treat an immune side effect. Treatment of serious inflammation can be lifesaving. Keep a written record of any steroid dose and taper.

Discuss vaccines before booking. The timing and type depend on your treatment, immune status and any steroids or other medicines you receive. Tell the vaccinating clinician about the complete treatment plan. Avoid relying on advice intended for a different cancer regimen.

Everyday life during treatment

There is no need to isolate from loved ones simply because you receive these antibodies. Plan activities around your energy and appointment schedule. Gentle activity is reasonable when you feel able, but stop and seek advice for chest pain, dizziness or unexpected breathlessness.

Avoid alcohol unless your liver team specifically confirms what is safe for you. Check painkillers with the team because liver disease, bleeding risk and kidney function affect the choice. Do not treat a new severe headache or abdominal pain repeatedly with painkillers instead of reporting it.

For travel, carry medicine names, the treatment card and hospital contact details. Discuss long journeys, insurance and access to medical care before booking. If you have a central line, follow the unit's care instructions and report redness, pain, leakage or fever.

Fertility, pregnancy and breastfeeding

These treatments can harm a developing baby. Tell the team immediately if pregnancy occurs or is suspected. Discuss reliable contraception before treatment rather than waiting for a missed period. Atezolizumab US information requires contraception during treatment and for at least five months afterwards; bevacizumab requires six months. For the combination, follow the longer applicable period and your local product advice.

Do not breastfeed during treatment. US information specifies five months after atezolizumab and six months after bevacizumab; the team should confirm the final date using the actual last doses. Bevacizumab may affect ovarian function. If future parenthood matters to you, ask about fertility assessment or preservation before starting.

After a pause or the end of treatment

The team may pause one medicine or both, depending on the problem. Atezolizumab is generally managed by withholding or stopping rather than reducing its dose. Bevacizumab also has interruption and discontinuation rules. Only the oncology team can decide whether continuing one component is appropriate.

Continue the agreed blood tests, blood-pressure checks and treatment for side effects. Keep the alert card and report new immune symptoms after the course ends. When care is transferred, ask for a summary including drug names, last doses, significant toxicities and any continuing steroid or hormone treatment.

Frequently asked questions